Skip to main content
Peter Sordillo, MD, Oncology, New York, NY

PeterPaulSordilloMD, M.A., M.Phil, PhD, M.S.

Oncology New York, NY

Breast Cancer, Gastrointestinal Cancer, Neuro-Oncology, Sarcoma

Attending Staff, Oncology and Hematology, Lenox Hill Hospital; Research Consultant, IUSL, Physics Department, CCNY; Vice-President, Chief Science and Medical Officer, SignPath Pharma, Inc.

Dr. Sordillo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Sordillo's full profile

Already have an account?

  • Office

    51 East 82nd Street
    New York, NY 10028
    Phone+1 917-922-9540

Summary

  • Peter P. Sordillo, M.D., PhD is an oncologist in New York, NY, affiliated with Lenox Hill Hospital. He is also Vice-President and Chief Scientific and Medical Officer at SignPath Pharma, a biotechnology firm: and Research Consultant, Institute for Ultrafast Spectroscopy and Lasers, Physics Department, City University of New York.
  • PETER P. SORDILLO, MD, PHD, MS

    Books and Book Chapters

    PETER P. SORDILLO, MD, M.A., MPhil, PhD, M.S.

    Book: Short-Wavelength Infrared Windows for Biochemical Applications. Laura Sordillo and Peter P. Sordillo (editors). SPIE Press, 2022.

Clinical Expertise

  • Glioblastoma, Pancreatic cancer, Colon cancer, Medical Oncology and Hematology, Optics and Photonics, Causality and Metaphysics, Quantum Physics and Quantum Computing, Soft-tissue Sarcoma

Education & Training

  • New York University
    New York UniversityMS, Physics, 1991 - 2001
  • Columbia University Graduate School of Arts and Sciences
    Columbia University Graduate School of Arts and SciencesPhD, Philosophy (Quantum Mechanics and Causality), 1982 - 1990
  • Columbia University
    Columbia UniversityMPhil, Philosophy, 1980 - 1982
  • Columbia University
    Columbia UniversityM.A., Philosophy, 1978 - 1980
  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1977 - 1980
  • Zucker School of Medicine at Hofstra/Northwell at Lenox Hill Hospital
    Zucker School of Medicine at Hofstra/Northwell at Lenox Hill HospitalResidency, Internal Medicine, 1974 - 1977
  • New York Medical College
    New York Medical CollegeClass of 1974
  • Columbia College
    Columbia College AB, major - Philosophy; minor - Biochemistry (Pre- Medical), English Literature, 1966 - 1970

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1975 - 2026
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Fellow American College of Physicians, 1984
  • Junior Faculty Clinical Award American Cancer Society, 1982-1984
  • Basic Science Research Award, "The Effects of Chemotherapy on Tumor Cell Growth in the Nude Mouse" Memorial Sloan-Kettering Cancer Center, 1979
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc�) in patients with locally advanced or metastatic cancer  
    Greil, R., Greil-Ressler, S., Weiss, L., Sch�nlieb, C., Magnes, T., Radl, B., Bolger, G.T., Vcelar, B. and Sordillo, P.P., Cancer chemotherapy and pharmacology, 1/1/2018
  • Distribution of curcumin and THC in peripheral blood mononuclear cells isolated from healthy individuals and patients with chronic lymphocytic leukemia  
    Bolger, G.T., Licollari, A., Tan, A., Greil, R., Pleyer, L., Vcelar, B., Majeed, M. and Sordillo, P.P., Anticancer research, 1/1/2018
  • Pharmacokinetics of liposomal curcumin (Lipocurc�) infusion: effect of co-medication in cancer patients and comparison with healthy individuals  
    Bolger, G.T., Licollari, A., Tan, A., Greil, R., Vcelar, B., Greil-Ressler, S., Weiss, L., Sch�nlieb, C., Magnes, T., Radl, B., Majeed, M. and Sordillo, P.P., Cancer chemotherapy and pharmacology, 1/1/2018
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Alzheimer�s disease: label-free fluorescence shows increases in indoleamine 2,3-dioxygenase (IDO) activity in affected areas of the brain.
    Sordillo, L.A., Zhang, L., Shi, L., Sordillo, P.P. and Alfano, R.R., Optical Biopsy XVII: Toward Real-Time Spectroscopic Imaging and Diagnosis; International Society for Optics and Photonics, 1/1/2019
  • Advances in medical applications using SWIR light in the wavelength range from 1600 to 2350 nm.
    Sordillo, L.A., Zhang, L., Shi, L., Sordillo, P.P. and Alfano, R.R., Optical Biopsy XVII: Toward Real-Time Spectroscopic Imaging and Diagnosis; International Society for Optics and Photonics, 1/1/2019
  • Optical fluorescence to assess abnormal tryptophan metabolic activity in brain samples from Alzheimer�s patients.
    Sordillo, L.A., Zhang, L., Shi, L., Sriramoju, V., Sordillo, P.P. and Alfano, R.R., CLEO: Applications and Technology; Optical Society of America, 1/1/2018
  • Join now to see all

Other

  • Suppression of Cytokine Release and Cytokine Storm. 
    Sordillo, P.P., Helson, L, Burgess S.W and Shaw W.A., Patent: #20, 160, 184, 330

Press Mentions

  • SignPath Pharma Reports Extremely Beneficial Blood Level Results of Its Phase 1b Clinical Trials of Liposomal Curcumin in Advanced Cancer Patients as Published in the Cancer Research Journal “Cancer Chemotherapy and Pharmacology”
    SignPath Pharma Reports Extremely Beneficial Blood Level Results of Its Phase 1b Clinical Trials of Liposomal Curcumin in Advanced Cancer Patients as Published in the Cancer Research Journal “Cancer Chemotherapy and Pharmacology”October 24th, 2018